Strengthening Northern Ireland’s health and economy through life sciences leadership
By Marion Laverty, Head of Public Affairs, Northern Ireland, Association of the British Pharmaceutical Industry (ABPI)
The pharmaceutical sector plays an important role in Northern Ireland’s economy, providing skilled jobs and supporting economic growth. Northern Ireland has key strengths which make it an attractive location for life sciences investment, including a robust academic base, an integrated health and social care system, and a collaborative culture that supports innovation. Together, these characteristics create a strong platform for Northern Ireland to build on and become a place where research, policy and cross-sector partnership deliver better outcomes for patients and society.
Our work in Northern Ireland is guided by a clear ambition: to work in partnership with government, the Health and Social Care (HSC) system, industry, and wider stakeholders to improve health outcomes, while supporting economic growth and innovation.
Three areas illustrate how this ambition is being delivered: industry investment in clinical trial infrastructure through the VPAG Investment Programme; the ABPI’s contribution to the work reforming medicines access pathways; and the development of bespoke partnership guidance to support collaboration between industry and the health system.
Driving investment and innovation through the VPAG Investment Programme
The 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) agreement between the UK government and the pharmaceutical industry is known primarily as a mechanism for controlling medicines spending. However, it is also aimed at driving investment in the UK’s life sciences ecosystem. Through the world-first, public-private partnership of the VPAG Investment Programme, industry is committing around £400 million to strengthen clinical research, data, and manufacturing capability across the whole of the UK, with Northern Ireland firmly included.
A strong example is the recent opening of the Commercial Research and Development Centre (CRDC) at the Ulster Hospital. This clinical trial centre expands Northern Ireland’s dedicated capacity and the staff to deliver commercial research, giving patients earlier access to innovative medicines and therapies while attracting global investment. The funding will also support a mobile clinical trial recruitment vehicle, increasing inclusion in research from those living with the greatest burden of disease.
Clinical trials help give patients access to the latest medicines, create high-value jobs, and strengthen links between industry, universities, and the health service. In a competitive international market, having the right infrastructure, expertise, speed, and reliability is essential to attract this globally mobile investment.
The ABPI has worked with partners to ensure Northern Ireland benefits from UK-wide investment and that local research and development strengths are recognised and built upon. The CRDC is an important step, but continued collaboration is needed to build capacity, streamline processes and offer a compelling proposition to global pharmaceutical companies.
Improving access to medicines through system reform
Innovation and investment must translate into timely access to medicines for patients. Like other parts of the UK, Northern Ireland faces challenges in moving new medicines from regulatory approval to routine use, meaning patients can experience avoidable delays in access to treatments.
In this context, the Department of Health’s Review of Access Pathways for Medicines within Health and Social Care Northern Ireland was a significant initiative. The ABPI contributed the perspective of research-based pharmaceutical companies, with a shared objective of improving efficiency, transparency, and predictability, while maintaining robust decision-making and value for money.
The publication of the review’s recommendations marked an important milestone, but implementation is critical. The ABPI brings together member companies to work alongside the Department of Health and stakeholders to help deliver the recommended reforms.
Improving access to medicines also brings wider benefits, helping people stay healthier for longer, reducing pressure on health and social care services, and supporting participation in work and community life.
Enabling partnership through bespoke guidance
Partnership working between the pharmaceutical industry and the health service has evolved, with growing recognition that industry can contribute expertise, digital tools, and improved diagnostic pathways for patients, alongside the medicines we produce. Realising this potential requires trust, clarity, and clear routes to collaboration.
In Northern Ireland, there is a bespoke route to partnership through the Health and Social Care (HSC) Industry Partnership – a unique arrangement that does not exist elsewhere in the UK. Through this route, the ABPI has worked with the NI NHS Confederation (NICON), supported by the Department of Health’s Medicines Optimisation Innovation Centre (MOIC), to develop tailored guidance for industry partnerships with the HSC system. This guidance reflects Northern Ireland’s integrated health and social care structures and distinct policy environment.
It provides a practical framework for ethical, transparent, and system-wide partnerships focused on patient benefit, supporting a more confident, consistent, and strategic approach to collaboration across Northern Ireland’s health and social care system.
A shared commitment to better outcomes
Engagement in medicines access reform and partnership guidance is helping to modernise systems, improve patient experience and strengthen collaboration across health and social care.
The ABPI remains committed to playing its part as a constructive partner to the Northern Ireland Executive, the Department of Health, the HSC, academia, and the voluntary sector.
A strong life sciences sector and an effective health system are economic and societal assets. By working together to support innovation, improve access to medicines and build trusted partnerships, Northern Ireland can be a place where people live healthier lives and innovation thrives.
As Head of Public Affairs for the ABPI in Northern Ireland, I am proud of the progress made and clear that there is more to do. The opportunity now is to build on these foundations and maintain a strong focus on outcomes – for patients, the health system, and Northern Ireland as a whole.